David M. Ryckman

Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth

Denis Drygin, Amy Lin, Josh Bliesath et al. · Cancer Research · 2010 · 621 citations

Life Sciences, Medicinal Chemistry, Oncology +17

Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53

Megan J. Bywater, Gretchen Poortinga, Elaine Sanij et al. · Cancer Cell · 2012 · 560 citations · Full text

Life Sciences, Molecular Biology, Oncology +16

CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy

Adam Siddiqui-Jain, Denis Drygin, Nicole Streiner et al. · Cancer Research · 2010 · 513 citations

Medicine, Oncology, Pharmacology +16

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer

Fabrice Pierre, Peter Chua, Sean O’Brien et al. · Journal of Medicinal Chemistry · 2010 · 299 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Unprecedented Selectivity and Structural Determinants of a New Class of Protein Kinase CK2 Inhibitors in Clinical Trials for the Treatment of Cancer

Roberto Battistutta, Giorgio Cozza, Fabrice Pierre et al. · Biochemistry · 2011 · 174 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +16